Rosebud Biosciences
Rosebud Biosciences accelerates drug development by screening drugs against organoids (micro-organs) that have the same gene mutations as the patients. We partner with therapeutics companies to screen their drugs, and we perform our own drug discovery for rare diseases that have no existing treatments. Our organoids are also fetal-like and enable discovery of novel drug targets for pediatric diseases. This technology was validated at Stanford, published in a prestigious journal, and has already led to the discovery of a drug target in a pediatric heart disease that could not have been found using traditional disease models.
Vendors
0Third parties this company currently discloses, grouped by function when classified.
No disclosed vendors yet
Vendors appear only once a public disclosure or other published evidence names them.
Customers
0Companies whose current disclosures name this company as a vendor.
No observed customers yet
Customers appear when another company's current disclosure names this company as a vendor.
Potential customers
0Companies using another vendor in one of Rosebud Biosciences’s categories, excluding Rosebud Biosciences’s observed customers.
No potential customers found
Potential customers appear after Rosebud Biosciences has a category assignment and current vendor relationships can be compared.